MX2010009574A - 2-aminoquinolinas. - Google Patents

2-aminoquinolinas.

Info

Publication number
MX2010009574A
MX2010009574A MX2010009574A MX2010009574A MX2010009574A MX 2010009574 A MX2010009574 A MX 2010009574A MX 2010009574 A MX2010009574 A MX 2010009574A MX 2010009574 A MX2010009574 A MX 2010009574A MX 2010009574 A MX2010009574 A MX 2010009574A
Authority
MX
Mexico
Prior art keywords
aminoquinolines
medicaments
concerned
manufacture
pharmaceutical compositions
Prior art date
Application number
MX2010009574A
Other languages
English (en)
Inventor
Claus Riemer
Sabine Kolczewski
Juergen Wichmann
Lucinda Steward
Olivier Roche
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010009574A publication Critical patent/MX2010009574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se relaciona con derivados de 2-aminoquinolina como antagonistas de receptor 5-HT5A, su elaboración, composiciones farmacéuticas que los contienen y su uso como medicamentos.
MX2010009574A 2008-03-05 2009-02-23 2-aminoquinolinas. MX2010009574A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08152327 2008-03-05
PCT/EP2009/052100 WO2009109477A1 (en) 2008-03-05 2009-02-23 2-aminoquinolines

Publications (1)

Publication Number Publication Date
MX2010009574A true MX2010009574A (es) 2010-09-24

Family

ID=40671014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009574A MX2010009574A (es) 2008-03-05 2009-02-23 2-aminoquinolinas.

Country Status (11)

Country Link
US (1) US8183380B2 (es)
EP (1) EP2262789A1 (es)
JP (1) JP2011513350A (es)
KR (1) KR20100119825A (es)
CN (1) CN101959876A (es)
AU (1) AU2009221375A1 (es)
BR (1) BRPI0909634A2 (es)
CA (1) CA2716122A1 (es)
IL (1) IL207698A0 (es)
MX (1) MX2010009574A (es)
WO (1) WO2009109477A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699697A1 (en) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5ht5a receptor antagonists
EP2252372A1 (en) * 2008-03-07 2010-11-24 F. Hoffmann-La Roche AG 2-aminoquinolines
RS58960B1 (sr) 2013-09-09 2019-08-30 Peloton Therapeutics Inc Aril etri i njihova primena
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144825A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
CN108264535A (zh) 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用
WO2024044792A1 (en) 2022-08-26 2024-02-29 Am Chemicals Llc Universal solid supports and phosphoramidite building blocks for oligonucleotide synthesis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147094A1 (en) * 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
EP1450801A4 (en) * 2001-11-27 2010-10-27 Merck Sharp & Dohme 2-AMINOQUINOLINE COMPOUNDS
MXPA05009722A (es) * 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
AU2007329064C1 (en) * 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag 2-Aminoquinolines as 5-HT(5A) receptor antagonists
CA2699697A1 (en) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5ht5a receptor antagonists
EP2262773A1 (en) * 2008-03-07 2010-12-22 F. Hoffmann-La Roche AG 2-aminoquinoline derivatives
EP2252372A1 (en) * 2008-03-07 2010-11-24 F. Hoffmann-La Roche AG 2-aminoquinolines
CA2716907A1 (en) * 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht5a receptor antagonists

Also Published As

Publication number Publication date
JP2011513350A (ja) 2011-04-28
WO2009109477A1 (en) 2009-09-11
IL207698A0 (en) 2010-12-30
AU2009221375A1 (en) 2009-09-11
KR20100119825A (ko) 2010-11-10
BRPI0909634A2 (pt) 2015-09-22
CA2716122A1 (en) 2009-09-11
EP2262789A1 (en) 2010-12-22
US8183380B2 (en) 2012-05-22
CN101959876A (zh) 2011-01-26
US20090227570A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
MX2010009574A (es) 2-aminoquinolinas.
MX2010003001A (es) Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
IN2012DN02177A (es)
IN2012DN02702A (es)
IN2012DN00754A (es)
EP2121658A4 (en) PIPERAZINYLPROPYLPYRAZOL DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MY181898A (en) Heterocyclic compounds and uses thereof
MY153915A (en) Organic compounds
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
IL214425A (en) Converted metastatic heterocyclic compounds, their pharmaceutical preparations and their uses
HK1120442A1 (en) Novel opioid antagonists
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
MX2009009690A (es) Derivados de tiazolidina como antagonistas del receptor de orexina.
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
TW200740814A (en) Compounds
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
IL210549A (en) Pipedrine - Quinocosalin-Mediated Conjugated Drugs
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина

Legal Events

Date Code Title Description
FG Grant or registration